CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Mifepristone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02354170
NCT02354170Phase 2Completed
CompareCT.gov

Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)

Roger Goldberg, M.D., MBA·interventional·Posted Feb 3, 2015·Updated Jul 26, 2017

In Brief

A Phase 2 clinical trial evaluating Mifepristone and Placebo for Central Serous Chorioretinopathy. Completed, enrolled 16 participants across 2 sites.

Detailed Summary

The goal of the study is to assess the efficacy and safety of mifepristone 300 or 900-mg once-daily dosing by mouth for 4 weeks in patients with central serous chorioretinopathy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Serous Chorioretinopathy
CountriesUnited States
CollaboratorsOphthalmic Consultants of Boston

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 3, 2015
Enrollment StartJan 1, 2015
Primary CompletionApr 27, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.4 years ago

Interventions

Mifepristonedrug

Placebodrug